Alnylam Pharmaceuticals stock hits all-time high at $311.24

Alnylam Pharmaceuticals (NASDAQ:ALNY) stock reached an all-time high of $311.24, marking a significant milestone for the $40.23 billion biotech company. According to InvestingPro analysis, the stock is currently trading slightly above its Fair Value, with analyst price targets ranging from $212 to $500. Over the past year, Alnylam Pharmaceuticals has experienced a remarkable 1-year change of 100.88%, reflecting strong investor confidence and robust performance. The company’s 17.21% revenue growth and strong liquidity position, with a current ratio of 3.04, underscore its growth trajectory and impact on the biotechnology sector. The stock’s ascent to this new peak highlights the ongoing interest and optimism surrounding Alnylam’s innovative approaches and strategic advancements in the pharmaceutical industry. InvestingPro subscribers have access to 12 additional investment tips and a comprehensive Pro Research Report that provides deeper insights into Alnylam’s financial health and growth prospects.

In other recent news, Alnylam Pharmaceuticals announced that the European Commission has approved its RNAi therapeutic, AMVUTTRA, for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This approval is based on the results of the HELIOS-B Phase 3 study, which demonstrated significant reductions in mortality and cardiovascular events. RBC Capital and H.C. Wainwright both maintained positive ratings on Alnylam, with RBC Capital setting a price target of $330 and H.C. Wainwright at $500, citing strong market performance and future growth prospects. RBC noted that the launch of Amvuttra has exceeded expectations, with substantial formulary inclusion and minimal payer resistance. Analysts from H.C. Wainwright highlighted Alnylam’s expanding pipeline, including upcoming pivotal studies for new treatments. Additionally, Alnylam’s former CEO, John Maraganore, has joined the board of Axion Bio, a subsidiary of Instil Bio, to advance cancer therapy initiatives. Alnylam’s recent developments indicate a robust trajectory in both its current and future product offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.